Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Blinded outcomes and angina assessment of coronary bioresorbable scaffolds: 30-day and 1-year results from the ABSORB IV randomised trial.
Stone GW, Ellis SG, Gori T, Metzger DC, Stein B, Erickson M, Torzewski J, Williams J Jr, Lawson W, Broderick TM, Kabour A, Piegari G, Cavendish J, Bertolet B, Choi JW, Marx SO, Généreux P, Kereiakes DJ; ABSORB IV Investigators. Stone GW, et al. Among authors: cavendish j. Lancet. 2018 Oct 27;392(10157):1530-1540. doi: 10.1016/S0140-6736(18)32283-9. Epub 2018 Sep 25. Lancet. 2018. PMID: 30266412 Clinical Trial.
Atrial shunt device for heart failure with preserved and mildly reduced ejection fraction (REDUCE LAP-HF II): a randomised, multicentre, blinded, sham-controlled trial.
Shah SJ, Borlaug BA, Chung ES, Cutlip DE, Debonnaire P, Fail PS, Gao Q, Hasenfuß G, Kahwash R, Kaye DM, Litwin SE, Lurz P, Massaro JM, Mohan RC, Ricciardi MJ, Solomon SD, Sverdlov AL, Swarup V, van Veldhuisen DJ, Winkler S, Leon MB; REDUCE LAP-HF II investigators. Shah SJ, et al. Lancet. 2022 Mar 19;399(10330):1130-1140. doi: 10.1016/S0140-6736(22)00016-2. Epub 2022 Feb 1. Lancet. 2022. PMID: 35120593
5-Year Outcomes After Bioresorbable Coronary Scaffolds Implanted With Improved Technique.
Stone GW, Kereiakes DJ, Gori T, Metzger DC, Stein B, Erickson M, Torzewski J, Kabour A, Piegari G, Cavendish J, Bertolet B, Stockelman KA, West NEJ, Ben-Yehuda O, Choi JW, Marx SO, Spertus JA, Ellis SG; ABSORB IV Investigators. Stone GW, et al. Among authors: cavendish j. J Am Coll Cardiol. 2023 Jul 18;82(3):183-195. doi: 10.1016/j.jacc.2023.05.003. Epub 2023 May 17. J Am Coll Cardiol. 2023. PMID: 37207924 Free article. Clinical Trial.
Severe ostial saphenous vein graft disease leading to acute coronary syndromes following proximal aorto-saphenous anastomoses with the symmetry bypass connector device: is it a suture device or a "stent"?
Cavendish JJ, Penny WF, Madani MM, Keramati S, Ben-Yehuda O, Blanchard DG, Mahmud E, Perricone A, Tsimikas S. Cavendish JJ, et al. J Am Coll Cardiol. 2004 Jan 7;43(1):133-9. doi: 10.1016/j.jacc.2003.09.028. J Am Coll Cardiol. 2004. PMID: 14715195 Free article.
Elevated plasma fibrinogen level predicts suboptimal response to therapy with both single- and double-bolus eptifibatide during percutaneous coronary intervention.
Mahmud E, Cavendish JJ, Tsimikas S, Ang L, Nguyen C, Bromberg-Marin G, Schnyder G, Keramati S, Palakodeti V, Penny WF, DeMaria AN. Mahmud E, et al. Among authors: cavendish jj. J Am Coll Cardiol. 2007 Jun 5;49(22):2163-71. doi: 10.1016/j.jacc.2007.03.019. Epub 2007 May 18. J Am Coll Cardiol. 2007. PMID: 17543636 Free article.
Embolic protection of saphenous vein graft percutaneous interventions.
Carter LI, Golzar JA, Cavendish JJ, Dixon SR. Carter LI, et al. Among authors: cavendish jj. J Interv Cardiol. 2007 Oct;20(5):351-8. doi: 10.1111/j.1540-8183.2007.00284.x. J Interv Cardiol. 2007. PMID: 17880331 Free article. Review. No abstract available.
52 results